Payment overview · 2025
General Payments
$590.55
33 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Ryan Rawls, MD
Allopathic & Osteopathic Physicians|Family Medicine · PURVIS, MS · NPI 1114488095
Verified facts
What the public records show
CMS Open Payments records show Christopher Ryan Rawls, MD received $590.55 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.86 | 26.2% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.20 | 12.7% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $60.77 | 10.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.17 | 7.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.81 | 6.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.28 | 6.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.61 | 6.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.80 | 5.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.58 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.06 | 3.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.14 | 2.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.83 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.94 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $590.55 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.20 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $60.77 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 86 |
| Prednisone | Prednisone | 256 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 215 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 67 |
| Gabapentin | Gabapentin | 203 | 70 |
| Cefdinir | Cefdinir | 200 | 147 |
| Doxycycline Hyclate | Doxycycline Hyclate | 182 | 147 |
| Losartan Potassium | Losartan Potassium | 160 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 81 |
| Omeprazole | Omeprazole | 148 | 52 |
| Lisinopril | Lisinopril | 147 | 55 |
| Cefuroxime | Cefuroxime Axetil | 146 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 146 | 43 |
| Levofloxacin | Levofloxacin | 142 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 49 |
| Furosemide | Furosemide | 119 | 49 |
| Trazodone Hcl | Trazodone Hcl | 107 | 41 |
| Alprazolam | Alprazolam | 100 | 36 |
| Pregabalin | Pregabalin | 100 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 22 |
| Jardiance | Empagliflozin | 80 | 23 |
| Famotidine | Famotidine | 79 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 30 |
| Tramadol Hcl | Tramadol Hcl | 74 | 36 |
| Metformin Hcl Er | Metformin Hcl | 72 | 27 |
| Potassium Chloride | Potassium Chloride | 71 | 25 |
| Buspirone Hcl | Buspirone Hcl | 69 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 28 |
| Memantine Hcl | Memantine Hcl | 69 | 20 |
| Mounjaro | Tirzepatide | 68 | 16 |
| Azithromycin | Azithromycin | 67 | 62 |
| Meloxicam | Meloxicam | 67 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 21 |
| Ozempic | Semaglutide | 64 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 23 |
| Ezetimibe | Ezetimibe | 62 | 22 |
| Metformin Hcl | Metformin Hcl | 62 | 23 |
| Ondansetron Odt | Ondansetron | 62 | 33 |
| Clonazepam | Clonazepam | 61 | 13 |
| Glimepiride | Glimepiride | 61 | 23 |
| Lorazepam | Lorazepam | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 22 |
| Carvedilol | Carvedilol | 58 | 24 |
| Fluconazole | Fluconazole | 58 | 41 |
| Mupirocin | Mupirocin | 57 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 13 |
| Methylprednisolone | Methylprednisolone | 53 | 52 |
| Clarithromycin | Clarithromycin | 51 | 40 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 19 |
| Sertraline Hcl | Sertraline Hcl | 51 | 18 |
| Eliquis | Apixaban | 49 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 19 |
| Spironolactone | Spironolactone | 48 | 18 |
| Valsartan | Valsartan | 47 | 17 |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 40 | 17 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Topiramate | Topiramate | 38 | 11 |
| Allopurinol | Allopurinol | 37 | 16 |
| Baclofen | Baclofen | 37 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 32 |
| Temazepam | Temazepam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 15 |
| Azelastine Hcl | Azelastine Hcl | 32 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 14 |
| Mirtazapine | Mirtazapine | 31 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Metronidazole | Metronidazole | 27 | 24 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 12 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | 14 |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Primidone | Primidone | 22 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Colchicine | Colchicine | 21 | 13 |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Prolia | Denosumab | 21 | 12 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | 13 |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 15 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 13 |
| Nystatin | Nystatin | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $590.55 · 33 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, EVENITY, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error